Fulcrum Therapeutics (NASDAQ: FULC) reports $352.3M cash estimate, updates investor presentation

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. reported a preliminary estimate of approximately $352.3 million in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is based on management’s estimates, is unaudited, and may change as year-end financial closing procedures are completed.

The company also released an updated corporate presentation with business and strategic updates, which it plans to use in investor meetings, including a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is available via webcast and as an exhibit to this report.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000168058100016805812026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Fulcrum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-38978	47-4839948
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
26 Landsdowne Street
Cambridge, Massachusetts				02139
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 651-8851

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		FULC		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Fulcrum Therapeutics, Inc., or Fulcrum, expects to report that it had cash, cash equivalents and marketable securities of approximately $352.3 million as of December 31, 2025.

The estimated cash figure is preliminary and unaudited, represents a management estimate as of the date of this Current Report on Form 8-K and is subject to completion of Fulcrum's financial closing procedures. Fulcrum's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated cash figure.

The information in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Fulcrum updated its corporate presentation to reflect certain business and strategic updates. Fulcrum intends to use this presentation in meetings with members of the investment community and others from time to time, including its presentation by management at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. PT (10:30 a.m. ET). A live webcast of the presentation and will be available on the “Events and Presentations” section of Fulcrum's website at https://ir.fulcrumtx.com. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:

99.1	Corporate slide presentation of Fulcrum Therapeutics, Inc. dated January 12, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FULCRUM THERAPEUTICS, INC.
Date:	January 12, 2026	By:	/s/ Alex C. Sapir
			Name: Alex C. Sapir Title: President and Chief Executive Officer

FAQ

What cash position does Fulcrum Therapeutics (FULC) expect as of December 31, 2025?

Fulcrum Therapeutics expects to report approximately $352.3 million in cash, cash equivalents and marketable securities as of December 31, 2025, based on preliminary, unaudited estimates.

Is Fulcrum Therapeutics’ reported cash balance audited?

No. The approximately $352.3 million cash, cash equivalents and marketable securities figure is a preliminary, unaudited management estimate and is subject to completion of financial closing procedures.

What did Fulcrum Therapeutics (FULC) disclose under Regulation FD in this 8-K?

Fulcrum disclosed that it updated its corporate presentation with business and strategic updates and will use it in meetings with the investment community, including a presentation at the 44th Annual J.P. Morgan Healthcare Conference.

Where can investors access Fulcrum Therapeutics’ updated corporate presentation?

A live webcast of the presentation and the updated slide deck are available in the “Events and Presentations” section of Fulcrum’s investor relations website and as Exhibit 99.1 to this report.

Will the information in this Fulcrum Therapeutics 8-K be deemed filed with the SEC?

The company states that information in Items 2.02 and 7.01, including Exhibit 99.1, is being furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act, except where specifically incorporated by reference.

What event is Fulcrum Therapeutics presenting at according to this 8-K?

Fulcrum plans to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 a.m. PT (10:30 a.m. ET).